---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126220"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:48:46.639749+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences reports FY2025 net loss of $2.3M; Zola revenues up 17% YoY; business combination terminated

## Summary
- Q4 2025 revenue $901K (-26% YoY); full-year revenue $4.86M (-4%). Net loss per share $1.71 vs $5.17 in 2024.
- Zola coconut water sales rose 17% to $701K in 2025; SG&A reduced 27% YoY.
- Roosevelt Resources terminated proposed business combination; Arcadia exercises preferred options for $2.1M gross proceeds.
- Cash and short-term investments totaled $4.56M at Dec 31, 2025, down from $4.24M cash alone a year earlier.
- Net cash used in operations improved 49% to $4.74M in 2025.

## SEC filing metadata
- accession: 0001193125-26-126220
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/0001193125-26-126220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/rkda-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126220
- JSON: https://secwatch.observer/filing/0001193125-26-126220.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126220.txt

## Key facts
- Earnings Releases
  Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
  - Period: the fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/0001193125-26-126220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.